[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Simon et al., 1994 - Google Patents

Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma

Simon et al., 1994

Document ID
14476919814132406899
Author
Simon B
Weinel R
Höhne M
Watz J
Schmidt J
Körtner G
Arnold R
Publication year
Publication venue
Gastroenterology

External Links

Snippet

Abstract Background/Aims: The pathogenesis of pancreatic cancer is poorly understood. The multigenetic nature of carcinogenesis has been best documented in colon cancer. The relevance of this model was suggested for other epithelial tumors. Only advanced stages of …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Simon et al. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma
US6245515B1 (en) Sequence specific DNA binding p53
Soong et al. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Asai et al. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells: Implication of the tumor suppressor genes for gene therapy
Pinyol et al. INK4a/ARFLocus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene
Bertorelle et al. Association of p53 gene and protein alterations with metastases in colorectal cancer
US8846629B2 (en) Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma
Vega et al. p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer
Kovalev et al. Loss of p53 function in uterine papillary serous carcinoma
Tsuda et al. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer
El-Mahdani et al. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation
CN111187835B (en) Pancreatic cancer target ERBB2 and application thereof in diagnosis and treatment
Kitagawa et al. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
Roth Molecular events in lung cancer
Mora et al. Regulation of expression of the early growth response gene‐1 (EGR‐1) in malignant and benign cells of the prostate
US20060141454A1 (en) Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
Fujino et al. Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer
Fong et al. Lung pathology: the molecular genetics of non-small cell lung cancer
WO2008075713A1 (en) Marker for diagnosis of cancer, and target molecule for therapy
US6929910B2 (en) Diagnostic and therapeutic methods using the H37 tumor suppressor gene
BUESORAMOS et al. Molecular abnormalities of MDM-2 in human sarcomas
US20090270479A1 (en) Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer
Fiszer‐Maliszewska et al. Results of p53 analysis in pediatric malignancies in Poland
KR100454871B1 (en) Use of thymosin beta-10 for gene therapy of solid malignant tumors
Gusterson et al. Application of molecular genetics and cytogenetics to breast cancer and soft tissue sarcomas